IPO Timeline
Broker Results (T-2)
2021-12-08
Some brokers release in afternoon
Grey Market (T-1)
2021-12-09
Afternoon
HKEX Allotment (T-1)
2021-12-09
Evening
Registrar Allotment (T-1)
2021-12-09
Evening
Listing Day (T)
2021-12-10
First day of trading
Cross-Market Price Comparison
| Other Listed Market | Shenzhen (SZSE) — 凯莱英 |
|---|---|
| Other Market Stock Code | 002821 |
| H-Share Offer Price | To be extracted |
| Other Market Price | Loading... |
| Reference Exchange Rate | Loading... |
| H-Share Offer Price Premium/Discount vs Other Market | Loading... |
Company Overview
| Stock Name | 凱萊英醫藥集團(天津)股份有限公司- H股 |
|---|---|
| Stock Code | 06821 |
| Company Full Name | 凱萊英醫藥集團(天津)股份有限公司- H股 |
| Industry | 醫療保健 |
| Principal Activities | 主要作為合同研發生產組織(CDMO)提供藥物開發及生產服務。 |
| Listing Date | 2021-12-10 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國天津市經濟技術開發區洞庭三街6號 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | https://www.asymchem.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 388.00 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 0% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 714,540,800 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 370.0 |
|---|---|
| First Day Open | HK$ 388.0 |
| First Day Change | -4.64% |
| First Day Volume | 2786450.0 |
| First Day Turnover | 1047110000.0 |
Use of Proceeds
| Use of Proceeds | 1、約20%(或1,370.0百萬港元)將用于進一步提高我們的小分子CDMO解決方案的產能及能力; 2、約35%(或2,397.4百萬港元)將用于加強我們新興服務并擴大我們的服務內容; 3、約20%(或或1,370.0百萬港元)將用于投資研發項目及保持我們的技術領先地位; 4、約15%(或1,027.5百萬港元)將用于選擇性地進行戰略投資及收購; 5、約10%(或685.0百萬港元)將用作營運資金及一般企業用途。 |
|---|
Underwriting Syndicate
Joint Sponsors (2)
高盛（亚洲）有限责任公司 CE ACC536
中信证券（香港）有限公司 CE AAK249
Overall Coordinators (2)
高盛（亚洲）有限责任公司 CE ACC536
中信里昂证券有限公司 CE AAB893
Joint Bookrunners (6)
高盛（亚洲）有限责任公司 CE ACC536
中信里昂证券有限公司 CE AAB893
Credit Suisse (Hong Kong) Limited CE AAO017
花旗环球金融亚洲有限公司 CE AAA137
国泰君安证券（香港）有限公司 CE ABY236
交银国际证券有限公司 CE APJ121
Joint Lead Managers (6)
高盛（亚洲）有限责任公司 CE ACC536
中信里昂证券有限公司 CE AAB893
Credit Suisse (Hong Kong) Limited CE AAO017
花旗环球金融亚洲有限公司 CE AAA137
国泰君安证券（香港）有限公司 CE ABY236
交银国际证券有限公司 CE APJ121
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Chairman | Hao Hong |
|---|---|
| Company Secretary | 徐向科;鄭程杰 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | Hao Hong及關連人士(36.85%) |
|---|
IPO Timeline
